4.5 Article

Will (or can) people pay for headache care in a poor country?

Journal

JOURNAL OF HEADACHE AND PAIN
Volume 13, Issue 1, Pages 67-74

Publisher

BMC
DOI: 10.1007/s10194-011-0398-1

Keywords

Headache-related health care; Burden of disease; Quality of life; Health economics; Willingness to pay; Republic of Georgia

Funding

  1. Allergan
  2. AstraZeneca
  3. Bayer
  4. Gruenenthal
  5. Mundipharma
  6. Pfizer
  7. World Headache Alliance
  8. International Headache Society
  9. European Headache Federation
  10. GlaxoSmithKline
  11. Pfizer Inc
  12. Allergan, Inc.
  13. Nycomed
  14. Desitin Pharmaceuticals GmbH
  15. Merck Serono
  16. German Federal Ministry for Research and Education
  17. Bayer Schering

Ask authors/readers for more resources

We asked whether attempts to introduce headache services in poor countries would be futile on grounds of cost and unsustainability. Using data from a population-based survey in the Republic of Georgia, an exemplary poor country with limited health care, and against the background of headache-attributed burden, we report on willingness to pay (WTP) for effective headache treatment. Consecutive households were visited in areas of Tbilisi (urban) and Kakheti (rural), together representative of Georgian habitation. Biologically unrelated adults were interviewed by medical residents using a structured ICHD-II-based diagnostic questionnaire, the MIDAS questionnaire and SF-36. The bidding-game method was employed to assess WTP. Of 1,145 respondents, 50.0% had episodic headache (migraine and/or tension-type headache) and 7.6% had headache on a parts per thousand yen15 days/month, which was not further diagnosed. MIDAS scores were higher in people with headache on a parts per thousand yen15 days/month (mean 11.2) than in those with episodic headache (mean 7.0; P = 0.004). People with headache had worse scores in all SF-36 sub-scales than those without, but no differences were found between headache types. Almost all (93%) respondents with headache reported WTP averaging USD 8 per month for effective headache treatment. WTP did not correlate with headache type or frequency, or with MIDAS or SF-36 scores. Headache is common and headache-attributed burden is high in Georgia, with a profound impact on HRQoL. Even those less affected indicated WTP for effective treatment, if it were available, that would on average cover costs, which locally are low. Headache services in a poor country are potentially sustainable.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available